FDA approved therapy for newly-diagnosed acute myeloid leukaemia patients
News
ABPI chief exec says no-deal Brexit is ‘not in the interest of patients’
Chief executive of trade body warns no-deal could affect medicines supply
Ten new medicines backed for EU approval
Dupixent, Forxiga and Opdivo were also recommended for therapeutic extensions
CQC assessment is a ‘wake-up call’ to government, says NHS Confed chief exec
Latest reports highlights need for improved access to mental health care
Sanofi’s Sarclisa bags NICE recommendation
Treatment is approved for relapsed/refractory multiple myeloma
Janssen’s psoriasis med Tremfya scores long-term safety and efficacy data
Treatment demonstrated positive outcomes for nearly five years
Astellas to acquire iota Biosciences following R&D partnership
Companies will develop ultra-small implantable medical devices
Roche signs deal with Dyno Therapeutics for gene therapy vectors
Dyno could receive up to $1.8bn in collaboration-associated payments
NIHR review identifies long-term effects of COVID-19
Review draws on experiences of patients and expert consensus
NICE recommends Novartis’ Mayzent on the heels of SMC approval
Drug is licensed for secondary progressive multiple sclerosis with active disease
EMA confirms eligibility for submission of Moderna’s COVID-19 vaccine
Primes company to submit vaccine candidate for rolling review
Bone Therapeutics showcases allogeneic cell therapy data
Data demonstrated a 90% successful lumbar vertebrae fusion rate at 24 months
J&J’s COVID-19 vaccine trial paused on safety concerns
Participant in phase III study developed unexplained illness
Redhill expands manufacturing for COVID-19 candidate
Company signs deals with two specialist pharmaceutical manufacturers
Iksuda Therapeutics exercises licensing rights from University of Goettingen
Agreement covers protein-alkylating, tumour-activated pro-drug payload series for ADC development
